Inside The PTAB's Seagen Cancer Drug Patent Decision
The latest chapter in the complex and multifaceted Daiichi Sankyo Inc. v. Seagen Inc.[1] patent dispute — concerning antibody-drug conjugate technology, or ADC, and pitting Seagen against Daiichi and its collaborator, AstraZeneca...To view the full article, register now.
Already a subscriber? Click here to view full article